Abstract 20: Targeting difficult targets with lysine-covalent ligands: Expanding the druggable space for covalent drugs
Abstract
Oncology drugs osimertinib, ibrutinib, neratinib, and afatinib have all been approved in very recent years by the FDA, and all target a cysteine that is present in proximity to the binding site of their respective targets. More recently, Amgen reported on AMG 510 as a first-in-class investigational drug designed to selectively and irreversibly target the KRAS G12C protein. These drugs rely on acrylamides moieties strategically incorporated in their chemical structures to selectively and efficiently react with binding site cysteine residues. Obviously, the approach is limited to drug targets that present a cysteine residue in proximity to the binding site, which often is not the case. This druggable target space for covalent drugs is called the Cysteinome. My laboratory has been developing and applying novel strategies aimed at deriving potent, selective, cell-permeable, and efficacious covalent therapeutics by designing agents that can selectively react with lysine residues (1,2). The approach relies on introducing stable aryl-fluorosulfates or sulfonyl-fluorides in drug leads to selectively and efficiently react with lysine residues. Because lysines are more ubiquitously found within the binding pocket of the target oncogenes, the approach defines a much larger target space for covalent drugs: the Lysinome. In addition, I will demonstrate that the approach is amenable also to tackle difficult targets such as those involving protein-protein interactions (PPIs). Hence, our…
Read the paper
Related studies
- Diagnosis and management of glutaric aciduria type I – revised recommendations
- EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
- Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency
- Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry
- Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin
- Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.